Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Communication
  • Published:

Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer

Oncogene volume 25, pages 4122–4127 (2006)Cite this article

Abstract

Fibroblast growth factors (FGF), and in particular FGF8, have been strongly implicated in prostate carcinogenesis. This study investigated the expression of Sef, a key inhibitory regulator of FGF signalling, in prostate cancer. In a panel of cell lines, hSef was detected in both androgen-dependent and independent cells but was significantly reduced in highly metastatic derivative clones. hSef expression was not influenced by androgenic stimulation. Forced downregulation of hSef by siRNA increased FGF8b induced cell migration (P=0.02) and invasion (P=0.007). Reduced hSef levels also enhanced FGF8b stimulated expression of MMP9 (P=0.005). mRNA in situ hybridization revealed hSef expression in 80% (8/10) of benign biopsies but in only 69% (23/33) of Gleason sum 4–7 and 35% (10/28) of Gleason sum 8–10 cancer biopsies (P=0.004). Quantitative PCR of microdissected glands confirmed this trend (P=0.001). hSef was expressed in 69% (27/39) of non-metastatic tumours but in only 18% (2/11) of metastatic tumours (P=0.004, n=50). hSef expression was next correlated with earlier data on FGF8b expression in a subgroup of cancers. In this cohort, 86% (19/22) of high-grade cancers expressed FGF8 but only 31% (7/22) expressed hSef. Positive FGF8 expression but a loss of hSef was observed in 88% (7/8) of metastatic tumours. In contrast, metastasis was evident in only 10% (1/10) of tumours, which co-expressed both FGF8 and hSef (P<0.001). These results suggest evidence that hSef is downregulated in advanced prostate cancer and might facilitate an enhanced tumorigenic response to FGFs. Further research into the role of hSef in cancer cell signalling and the mechanism of its downregulation may contribute to more effective targeting of growth factors in prostate cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY . (1999). Oncogene 18: 2755–2761.

  • Dorkin TJ, Bjartell A, Neal DE, Leung HY . (2000). BJU Int 86: 392–393.

  • Furthauer M, Lin W, Ang S, Thisse B, Thisse C . (2002). Nat Cell Biol 4: 170–174.

  • Gao AC, Lou W, Isaacs JT . (2000). Clin Cancer Res 6: 493–497.

  • Giri D, Ropiquet F, Ittmann M . (1999). Clin Cancer Res 5: 1063–1071.

  • Gnanapragasam VJ, Leung HY, Pulimood AS, Neal DE, Robson CN . (2001). Br J Cancer 12: 1928–1936.

  • Gnanapragasam VJ, Robson CN, Neal DE, Leung HY . (2002). Oncogene 21: 5069–5080.

  • Gnanapragasam V, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung HY . (2003). Br J Cancer 88: 1432–1438.

  • Gowardhan B, Douglas DA, Mathers ME, McKie AB, McCracken SR, Robson CN et al. (2005). Br J Cancer 92: 320–327.

  • Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. (2004). Cancer J Clin 54: 8–29.

  • Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A et al. (2004). JAMA 291: 2713–2719.

  • Koslowski JM, Fidler IJ, Campbell D, Xu Z, Kaighn ME, Hart IR. . (1984). Cancer Res 44: 3522–3529.

  • Kovalenko D, Yang X, Nadeau RJ, Harkins LK, Friesel R . (2003). J Biol Chem 278: 14087–14091.

  • Kwabi-Addo B, Ozen M, Ittmann M . (2004). Endocr Relat Cancer 11: 709–724.

  • Leung HY, Dickson C, Robson CN, Neal DE . (1996). Oncogene 12: 1833–1835.

  • Lin W, Furthauer M, Thisse B, Thisse C, Jing N, Ang S . (2002). Mech Dev 113: 163–168.

  • Lin W, Jing N, Basson MA, Dierich A, Licht J, Ang SL . (2005). Genesis 41: 110–115.

  • Mattila MM, Ruohola JK, Valve EM, Tasanen MJ, Seppanen JA, Harkonen PL . (2001). Oncogene 20: 2791–2804.

  • Ornitz D, Xu J, Colvin J, McEwen D, MacArthur C, Coulier F et al. (1996). J Biol Chem 271: 15292–15297.

  • Ozen M, Giri D, Ropiquet F, Mansukhani A, Ittmann M . (2001). J Natl Cancer Inst 93: 1783–1790.

  • Pettaway C, Pathak S, Greene G, Ramirez E, Wilson M, Killion J et al. (1996). Clin Cancer Res 2: 1627–1636.

  • Rudra-Ganguly N, Zheng J, Hoang A, Roy-Burman P . (1998). Oncogene 16: 1487–1492.

  • Ruohola J, Viitanen T, Valve E, Seppanen J, Loponen T, Keskitalo J et al. (2001). Cancer Res 61 (10): 4229–4237.

  • Song Z, Powell WC, Kasahara N, van Bokhoven A, Miller GJ, Roy-Burman P . (2000). Cancer Res 60: 6730–6736.

  • Song Z, Wu X, Powell WC, Cardiff RD, Cohen MB, Tin RT et al. (2002). Cancer Res 62: 5096–5105.

  • Torii S, Kusakabe M, Yamamoto T, Maekawa M, Nishida E . (2004). Dev Cell 7: 33–44.

  • Tsang M, Friesel R, Kudoh T, Dawid IB . (2002). Nat Cell Biol 4: 165–169.

  • Xiong S, Zhao Q, Rong Z, Huang G, Huang Y, Chen P et al. (2003). J Biol Chem 278: 50273–50282.

  • Yan G, Fukabori Y, McBride G, Nikolarapolous S, McKeehan WL . (1992). Mol Cell Biol 13: 4513–4522.

  • Yang RB, Ng CK, Wasserman SM, Komuves LG, Gerritsen ME, Topper JN . (2003). J Biol Chem 278: 33232–33238.

  • Yang X, Kovalenko D, Nadeau RJ, Harkins LK, Mitchell J, Zubanova O et al. (2004). J Biol Chem 279: 38099–38102.

Download references

Acknowledgements

This study was funded by Cancer Research UK (C1435/A4114), Newcastle upon Tyne Hospital Trustees.

Author information

Authors and Affiliations

  1. Urology Research Group, Northern Institute for Cancer Research, Medical School, University of Newcastle Upon Tyne, Framlington Place, Newcastle Upon Tyne, UK

    S Darby, K Sahadevan, C N Robson, H Y Leung & V J Gnanapragasam

  2. Department of Pathology, Royal Victoria Infirmary, Newcastle Upon Tyne, UK

    M M Khan

Authors
  1. S Darby
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Sahadevan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M M Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C N Robson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Y Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. V J Gnanapragasam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V J Gnanapragasam.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Darby, S., Sahadevan, K., Khan, M. et al. Loss of Sef (similar expression to FGF) expression is associated with high grade and metastatic prostate cancer. Oncogene 25, 4122–4127 (2006). https://doi.org/10.1038/sj.onc.1209428

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1209428

Keywords

This article is cited by

Search

Advanced search

Quick links